CONMED Co. (NYSE:CNMD - Get Free Report) declared a quarterly dividend on Tuesday, December 10th,RTT News reports. Stockholders of record on Friday, December 20th will be given a dividend of 0.20 per share on Friday, January 3rd. This represents a $0.80 annualized dividend and a dividend yield of 1.07%.
CONMED has a dividend payout ratio of 16.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect CONMED to earn $4.82 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 16.6%.
CONMED Trading Up 0.1 %
NYSE CNMD traded up $0.06 on Tuesday, hitting $74.75. 453,753 shares of the stock were exchanged, compared to its average volume of 480,047. The company's 50-day moving average price is $69.41 and its two-hundred day moving average price is $70.48. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06. CONMED has a 52-week low of $61.05 and a 52-week high of $117.27. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 0.93 and a beta of 1.46.
CONMED (NYSE:CNMD - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.06. The firm had revenue of $316.70 million for the quarter, compared to the consensus estimate of $318.46 million. CONMED had a net margin of 10.23% and a return on equity of 13.84%. Research analysts predict that CONMED will post 4.03 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on CNMD shares. StockNews.com lowered CONMED from a "buy" rating to a "hold" rating in a report on Friday, November 8th. Needham & Company LLC reiterated a "buy" rating and issued a $97.00 target price on shares of CONMED in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $79.80.
Get Our Latest Stock Analysis on CNMD
About CONMED
(
Get Free Report)
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
See Also
Before you consider CONMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CONMED wasn't on the list.
While CONMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
